HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques

Abstract : Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. These new tools have profoundly changed therapeutic management in oncology, with increasingly precise molecular characterization of tumors leading to increasingly personalized therapeutic targeting. Detection of circulating tumor cells and/or circulating tumor DNA in blood samples -so-called 'liquid biopsies'- can now provide a genetic snapshot of the patient's tumor through an alternative and less invasive procedure than biopsy of the tumor tissue itself. This procedure for characterizing and monitoring the disease in real time facilitates the search for possible relapses, the emergence of resistance, or emergence of a new therapeutic target. In the long term, it might also provide a means of early detection of cancer. These new approaches require the treatment of ever-increasing amounts of clinical data, notably, with the goal of calculating composite clinical-biological predictive scores. The use of artificial intelligence will be unavoidable in this domain, but it raises ethical questions and implications for the health-care system that will have to be addressed.
Document type :
Journal articles
Complete list of metadata

https://hal.sorbonne-universite.fr/hal-03534190
Contributor : Gestionnaire Hal-Su Connect in order to contact the contributor
Submitted on : Wednesday, January 19, 2022 - 11:52:14 AM
Last modification on : Friday, May 20, 2022 - 11:06:57 AM
Long-term archiving on: : Wednesday, April 20, 2022 - 6:28:54 PM

File

1-s2.0-S0007455121006822-main....
Publication funded by an institution

Identifiers

Citation

Alexandre Perrier, Pierre Hainaut, Alexandre Guenoun, Dinh-Phong Nguyen, Pierre-Jean Lamy, et al.. Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques. Bulletin du Cancer, John Libbey Eurotext, 2022, ⟨10.1016/j.bulcan.2021.11.010⟩. ⟨hal-03534190⟩

Share

Metrics

Record views

28

Files downloads

37